<DOC>
	<DOCNO>NCT02817464</DOCNO>
	<brief_summary>The purpose pharmacodynamic pharmacokinetic study identify dose TV-46046 ( within range 80 300 mg ) safe consistent contraceptive effect inject every 6 month .</brief_summary>
	<brief_title>Study Evaluate Suppression Ovulation Pharmacokinetics Medroxyprogesterone Acetate Following Administration TV-46046 Women With Ovulatory Cycle</brief_title>
	<detailed_description />
	<mesh_term>Medroxyprogesterone</mesh_term>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<criteria>regular menstrual cycle ( 24 35 day ) low risk pregnancy ( ie , sterilize , exclusively samesex partnership , monogamous relationship vasectomize partner , use nonhormonal IUD ) good general health determine medical history physical examination pregnant desire become pregnant subsequent 36 month normal mammogram within last year ( Part 1 ) additional criterion apply , please contact investigator information hypertension : systolic blood pressure ( BP ) ≥160 mm Hg diastolic BP ≥100 mm Hg vascular disease current history ischemic heart disease history stroke history thromboembolic event systemic lupus erythematosus positive ( unknown ) antiphospholipid antibody severe thrombocytopenia rheumatoid arthritis immunosuppressive therapy migraine aura unexplained vaginal bleeding diabetes strong family history breast cancer ( define one first degree relative , breast cancer occur menopause three family member , regardless degree relationship , male family member breast cancer ) , current history breast cancer , undiagnosed mass detect breast exam cervical cancer severe cirrhosis ( decompensated ) liver tumor know significant renal disease history medical treatment clinical depression use DepoProvera Contraceptive Injection Deposubcutaneous Provera 104 ( DMPA ) product past 12 month use follow medication within 1 month prior enrollment : investigational drug prohibit drug per protocol oral contraceptive , contraceptive ring patch levonorgestrel intrauterine system ( LNG IUS ) contraceptive implant use combine injectable contraceptive past 6 month le 3 month since end last pregnancy currently lactate use plan use prohibit drug per protocol next 18 month know sensitivity MPA inactive ingredient plan move another location next 24 month additional criterion apply , please contact investigator information</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>